This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
AB-FUBINACA: Difference between revisions
>LockPicker m Revised german legal status |
>LockPicker m Revised german legal status, merged redundant references |
||
| Line 23: | Line 23: | ||
*'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of AB-FUBINACA may be described as a warm, soft, pleasurable, all-encompassing tingling sensation that spreads over the body after initial ingestion. It maintains a consistent presence that quickly rises with the onset and hits its limit once the peak has been reached before immediately dissipating. At high doses, this can become uncomfortably intense. | *'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of AB-FUBINACA may be described as a warm, soft, pleasurable, all-encompassing tingling sensation that spreads over the body after initial ingestion. It maintains a consistent presence that quickly rises with the onset and hits its limit once the peak has been reached before immediately dissipating. At high doses, this can become uncomfortably intense. | ||
*'''[[Effect::Motor control loss]]''' - This substance causes a partial to moderate suppression of motor control which intensifies proportional to dose but rarely results in a complete inability to walk and perform basic movements. | *'''[[Effect::Motor control loss]]''' - This substance causes a partial to moderate suppression of motor control which intensifies proportional to dose but rarely results in a complete inability to walk and perform basic movements. | ||
*'''[[Effect::Appetite enhancement]]''' - As with many other cannabinoids, AB-FUBINACA causes an increase in appetite<ref>Mechoulam, R. (1984). Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press. ISBN 0-8493-5772-1.</ref>, known colloquially as "the munchies" in popular American and United Kingdom culture. Clinical studies and survey data have found that cannabis increases food enjoyment and interest in food.<ref>How Marijuana Works | http://science.howstuffworks.com/marijuana4.htm</ref> This is thought to be due to the way in which endocannabinoids in the hypothalamus activate cannabinoid receptors that are responsible for maintaining food intake.<ref> | *'''[[Effect::Appetite enhancement]]''' - As with many other cannabinoids, AB-FUBINACA causes an increase in appetite<ref>Mechoulam, R. (1984). Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press. ISBN 0-8493-5772-1.</ref>, known colloquially as "the munchies" in popular American and United Kingdom culture. Clinical studies and survey data have found that cannabis increases food enjoyment and interest in food.<ref name="HMW">How Marijuana Works | http://science.howstuffworks.com/marijuana4.htm</ref> This is thought to be due to the way in which endocannabinoids in the hypothalamus activate cannabinoid receptors that are responsible for maintaining food intake.<ref name="HMW"></ref> | ||
*'''[[Effect::Changes in felt gravity]]''' - AB-FUBINACA can cause vertigo with which the environment appears to be spinning or oscillating. At moderate doses, it can spontaneously induce the sensation of falling, which can be overwhelming and uncomfortable. | *'''[[Effect::Changes in felt gravity]]''' - AB-FUBINACA can cause vertigo with which the environment appears to be spinning or oscillating. At moderate doses, it can spontaneously induce the sensation of falling, which can be overwhelming and uncomfortable. | ||
*'''[[Effect::Perception of bodily heaviness]]''' ''or'' '''[[Perception of bodily lightness]]''' | *'''[[Effect::Perception of bodily heaviness]]''' ''or'' '''[[Perception of bodily lightness]]''' | ||
| Line 46: | Line 46: | ||
*'''[[Effect::Dream suppression]]''' | *'''[[Effect::Dream suppression]]''' | ||
*'''[[Effect::Immersion enhancement]]''' | *'''[[Effect::Immersion enhancement]]''' | ||
*'''[[Effect::Psychosis]]''' - The prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to psychosis<ref>Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short</ref>, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref>Every-Palmer, S. [[Synthetic cannabinoid]] use and psychosis: an explorative study. Journal of Drug and Alcohol Dependence 2011.</ref><ref>“Spice” Girls: Synthetic Cannabinoid Intoxication - The Journal of Emergency Medicine Volume 40, Issue 3, March 2011, Pages 296–299 (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0736467910008802</ref><ref>A Teenager With Agitation: Higher Than She Should Have Climbed - Pediatric Emergency Care: June 2010 - Volume 26 - Issue 6 - pp 462-465 | http://journals.lww.com/pec-online/Abstract/2010/06000/A_Teenager_With_Agitation__Higher_Than_She_Should.16.aspx</ref> | *'''[[Effect::Psychosis]]''' - The prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to psychosis<ref name="Arseneault2018">Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short</ref>, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref name="Every-Palmer">Every-Palmer, S. [[Synthetic cannabinoid]] use and psychosis: an explorative study. Journal of Drug and Alcohol Dependence 2011.</ref><ref name="Schneir2011">“Spice” Girls: Synthetic Cannabinoid Intoxication - The Journal of Emergency Medicine Volume 40, Issue 3, March 2011, Pages 296–299 (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0736467910008802</ref><ref name="Osterhoudt2010">A Teenager With Agitation: Higher Than She Should Have Climbed - Pediatric Emergency Care: June 2010 - Volume 26 - Issue 6 - pp 462-465 | http://journals.lww.com/pec-online/Abstract/2010/06000/A_Teenager_With_Agitation__Higher_Than_She_Should.16.aspx</ref> | ||
*'''[[Effect::Personal meaning enhancement]]''' | *'''[[Effect::Personal meaning enhancement]]''' | ||
*'''[[Effect::Increased music appreciation]]''' | *'''[[Effect::Increased music appreciation]]''' | ||
| Line 67: | Line 67: | ||
It is worth noting that this compound has been linked to multiple hospitalizations and deaths due to its use.<ref>Synthetic Cannabinoid–Related Illnesses and Deaths | http://www.nejm.org/doi/full/10.1056/NEJMp1505328</ref><ref>Suicide attempt with a mix of [[synthetic cannabinoids]] and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC | http://www.fsijournal.org/article/S0379-0738(16)00037-2/abstract</ref> | It is worth noting that this compound has been linked to multiple hospitalizations and deaths due to its use.<ref>Synthetic Cannabinoid–Related Illnesses and Deaths | http://www.nejm.org/doi/full/10.1056/NEJMp1505328</ref><ref>Suicide attempt with a mix of [[synthetic cannabinoids]] and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC | http://www.fsijournal.org/article/S0379-0738(16)00037-2/abstract</ref> | ||
It has often been recommended that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly increase [[emotion enhancement|one's current state of mind and emotions]]. Also, like [[THC]], prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to mental illness and psychosis<ref> | It has often been recommended that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly increase [[emotion enhancement|one's current state of mind and emotions]]. Also, like [[THC]], prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to mental illness and psychosis<ref name="Arseneault2018"></ref>, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref name="Every-Palmer"></ref><ref name="Schneir2011"></ref><ref name="Osterhoudt2010"></ref> | ||
As synthetic cannabinoids are active in the milligram range (with below 5mg being a typical dose), it is important to [[Dosage|use proper precautions when dosing]] to avoid a negative experience. | As synthetic cannabinoids are active in the milligram range (with below 5mg being a typical dose), it is important to [[Dosage|use proper precautions when dosing]] to avoid a negative experience. | ||
| Line 84: | Line 84: | ||
*'''China''': As of October 2015 AB-FUBINACA is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref> | *'''China''': As of October 2015 AB-FUBINACA is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref> | ||
*'''Germany''': AB-FUBINACA is controlled under Anlage II BtMG (Narcotics Act, Schedule II) | *'''Germany''': AB-FUBINACA is controlled under Anlage II BtMG (''Narcotics Act, Schedule II'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Anlage II BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 30, 2019|language=de}}</ref> as of December 13, 2014.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl114s1999.pdf|title=Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2014 Teil I Nr. 57|publication-date=December 12, 2014|access-date=December 19, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref> | ||
*'''Latvia''': AB-FUBINACA is a Schedule I drug.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Indazola-3-karbonilatvasinājumi) | http://likumi.lv/doc.php?id=121086</ref> | *'''Latvia''': AB-FUBINACA is a Schedule I drug.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Indazola-3-karbonilatvasinājumi) | http://likumi.lv/doc.php?id=121086</ref> | ||
*'''United Kingdom''': AB-FUBINACA is a class B drug under the third-generation synthetic cannabinoids generic definition, which came into effect on the 14th December 2016 and is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref> | *'''United Kingdom''': AB-FUBINACA is a class B drug under the third-generation synthetic cannabinoids generic definition, which came into effect on the 14th December 2016 and is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref> | ||